Psoriasis Clinical Trial
Official title:
Prevalence of Sleep Disturbances in Psoriasis
The purpose of this study is to compare the sleep quality of patients with psoriasis to patients without psoriasis.
In psoriasis, the burden of disease extends well beyond physical manifestations and can be
associated with significant physical, social and psychological impairments. The impact of
psoriasis on quality of life has been extensively investigated and demonstrates a negative
affect on activities of daily living including sleep. Sleep abnormalities have also been
reported in other dermatologic diseases including atopic dermatitis. However, there is
relatively little data on the impact of psoriasis on sleep quality and what factors are
likely to cause sleep disturbances. Obtaining this information is important because both
psoriasis and sleep disorders are associated with cardiovascular disease. A better
understanding of sleep problems in psoriasis may help to further our knowledge of psoriasis
co-morbidities.
Certain factors associated with psoriasis, including pruritus, depression, and
sleep-disordered breathing (obstructive sleep apnea) can independently affect sleep. It would
be of particular interest to assess the effect of these factors on sleep quality in psoriasis
subjects and the control group to determine what type of sleep problems exist among patients
with psoriasis.
This study involves the use of six questionnaires to be given to subjects with psoriasis
covering >10% BSA and 40 subjects without psoriasis matched for age, gender and BMI, as a
control population. The questionnaires will be given to subjects when they come for their
scheduled appointments. The surveys will be completed anonymously and will be collected by a
staff member when they are done. A physician will determine the participants' disease
severity using the Psoriasis Area and Severity Index (PASI) and will attach the score to
their questionnaire.
The questionnaires will cover sleep quality, depression, pruritis, insomnia, hypersomnia, and
sleep-disordered breathing. Subjects will be given standard instructions to follow written
directions on each questionnaire and will be given an unlimited amount of time to complete
the surveys.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |